The C3-1-TAg mice bearing primary breast tumors were MCT-primed for 2 weeks and then treated with anti-PD-1 antibody in combination with either IgG or CXCL16 NAb prior to STAT1 inhibitor treatment (Fig. 6c, Treatment Regimen 2 and Supplementary Fig. 6a). This evidence concerns the gene CXCL16 and breast neoplasm.